Nucleotide Binding Preference of the Monofunctional Platinum Anticancer-Agent Phenanthriplatin
The monofunctional platinum anticancer agent phenanthriplatin generates covalent adducts with the purine bases guanine and adenine. Preferential nucleotide binding was investigated by using a polymerase stop assay and linear DNA amplification with a 163-base pair DNA double helix. Similarly to cispl...
Main Authors: | Riddell, Imogen Anne, Johnstone, Timothy, Park, Ga Young, Lippard, Stephen J. |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Chemistry |
Format: | Article |
Language: | en_US |
Published: |
John Wiley & Sons
2016
|
Online Access: | http://hdl.handle.net/1721.1/103993 https://orcid.org/0000-0002-6801-0198 https://orcid.org/0000-0002-2693-4982 |
Similar Items
-
Understanding and Improving Platinum Anticancer Drugs - Phenanthriplatin
by: Johnstone, Timothy, et al.
Published: (2015) -
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile
by: Park, Ga Young, et al.
Published: (2013) -
Monofunctional and Higher-Valent Platinum Anticancer Agents
by: Wilson, Justin J., et al.
Published: (2015) -
Interaction of the New Monofunctional Anticancer Agent Phenanthriplatin With Transporters for Organic Cations
by: Hucke, Anna, et al.
Published: (2018) -
The effect of geometric isomerism on the anticancer activity of the monofunctional platinum complex
by: Zhou, Wen, et al.
Published: (2018)